US00287Y1091 - Common Stock - After market: 146.4 +0.12 (+0.08%)
After adding $208B in sales over two decades, AbbVie's (ABBV) monopoly over world's best selling drug Humira (adalimumab) is about to end as copycats enter. Read the full story here.
Dividend stocks are a hedge against volatile markets. Here are seven dividend stocks that you should buy now before you regret missing out.
You can count on them for passive income and growth over time.
A committee of the European Medicines Agency ((EMA)) said that Johnson & Johnson (JNJ) withdrew its application seeking expanded approval of blood cancer drug Imbruvica on Dec
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.
/PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World...
The pharmaceutical specialist is facing a pivotal year in 2023, thanks to growing competition.
Passive income is particularly welcome during tough market times.
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.
These dividend stocks can deliver both downside protection and capital appreciation.
Two newer immunology drugs look like big tickets to growth.
Looking at recently approved drugs and the pipelines of major pharmaceutical companies, there is no lack of therapies that could potentially be significant revenue drivers.Analytics...
At this point, the best thing to do is position your portfolio for potential downside with these top stocks to own.
These companies have what it takes to drive long-term share performance.
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
Allergan Aesthetics, a division of AbbVie (ABBV), has launched nationwide Juvederm Volux XC, long-lasting hyaluronic acid filler for severe loss of jawline definition.
Over the past 10 years, these stocks have each risen by more than 340%.
Last month, one of its anti-psychotic drugs received approval from the Food and Drug Administration for another indication.
/PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of the long-awaited SkinMedica® Even & Correct Collection....
This year isn't starting on the best of notes for the drugmaker.
The fountain of youth might not be a myth in the future.
The stock offers an attractive yield, but investors need to brace for declining revenue this year.
Germany-based research institute BioMed X is broadening an existing partnership with AbbVie (ABBV) to focus on immunology and tissue engineering.
These 3 Dividend Kings offer value and yield to investors and could outperform the group in 2023. That's good news for income investors.
Rely upon income-generating stocks to see your portfolio through times of upheaval.
AbbVie (ABBV) and Eli Lilly (LLY) have left a voluntary drug pricing agreement between the pharma industry and the U.K
Drugmakers Eli Lilly & Co. and AbbVie Inc. have pulled out of a voluntary drug-pricing agreement with the UK in a blow to the country’s attempts to control costs for medicines.
Steady growth and dividends in an evergreen industry like healthcare can be a winning investment strategy.